Go Deep
Eledon Pharmaceuticals, Inc.
Eledon Pharmaceuticals, Inc. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 18,581 | -2.6 | 5.76 | 0.01 | 222.85 |
| Oct 2026 | 18,789 | -2.5 | 5.54 | 0.01 | 213.63 |
| Oct 2026 | 18,743 | -2.6 | 5.59 | 0.01 | 215.56 |
| Oct 2026 | 19,068 | -2.4 | 5.24 | 0.01 | 201.74 |
| Oct 2026 | 18,998 | -2.4 | 5.32 | 0.01 | 204.80 |
| Oct 2026 | 18,778 | -2.5 | 5.55 | 0.01 | 213.81 |
| Oct 2026 | 18,766 | -2.5 | 5.56 | 0.01 | 213.76 |
| Oct 2026 | 18,673 | -2.6 | 5.66 | 0.01 | 217.10 |
Eledon Pharmaceuticals, Inc. Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 0.0 | 0.0 | 0.0 | 0.0 |
| Net Profit | -31,630,000.0 | -39,025,000.0 | -10,447,000.0 | -17,459,000.0 |
| EPS | -0.3 | -0.3 | — | -0.2 |
Eledon Pharmaceuticals, Inc. Revenue & Profit: Last 5 Years
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Revenue | 0.0 | 0.0 | 0.0 | 0.0 | — |
| Net Profit | -45,617,000.0 | -36,184,000.0 | -116,537,000.0 | -87,966,000.0 | — |
| EPS | -0.5 | -0.7 | -3.7 | -6.2 | — |
Eledon Pharmaceuticals, Inc. Balance Sheet
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Total Assets | 169,009,000.0 | 177,405,000.0 | 89,066,000.0 | 92,793,000.0 | — |
| Total Liabilities | 87,924,000.0 | 114,959,000.0 | 81,858,000.0 | 8,610,000.0 | — |
| Total Equity | 81,085,000.0 | 62,446,000.0 | 7,208,000.0 | 84,183,000.0 | — |
Owes vs Owns
Eledon Pharmaceuticals, Inc. owed $0.74 for every $1 it owned in Jun 2026, up from $0.09 in Dec 2022.
| Period | Jun 2026 | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
| Owes vs Owns | 0.74× | 0.52× | 0.65× | 0.92× | 0.09× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Eledon Pharmaceuticals, Inc. Assets & Liabilities Breakdown (USD millions)
What it owns — Dec 2025
Cash & short-term investments 78.9%Intangible assets 19.2%Other assets 1.3%
How it's funded — Dec 2025
Payables 2.1%Other liabilities 49.5%Shareholders' equity 48.0%
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 133.3 | 140.2 | 51.1 | 56.4 |
| Receivables | 0.5 | 0.6 | 0.0 | 0.0 |
| Inventory | 0.0 | 0.0 | 0.0 | 0.0 |
| Fixed assets (tangible) | 0.6 | 0.9 | 0.4 | 0.7 |
| Intangible assets | 32.4 | 32.4 | 32.4 | 32.4 |
| Long-term investments | 0.0 | 0.0 | 0.0 | 0.0 |
| Other assets | 2.2 | 3.3 | 5.2 | 3.3 |
| Liabilities & equity | ||||
| Short-term debt | 0.4 | 0.3 | 0.4 | 0.4 |
| Long-term debt | 0.3 | 0.6 | 0.0 | 0.4 |
| Payables | 3.6 | 5.8 | 1.0 | 2.2 |
| Other liabilities | 83.7 | 108.2 | 80.5 | 5.7 |
| Shareholders' equity | 81.1 | 62.4 | 7.2 | 84.2 |
| Net tangible assets | 48.7 | 30.1 | -25.2 | 51.8 |
Eledon Pharmaceuticals, Inc. Cash Flow
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Operating Activities | -62,341,000.0 | -47,271,000.0 | -39,527,000.0 | -28,424,000.0 | — |
| Investing Activities | 10,793,000.0 | -70,314,000.0 | -45,287,000.0 | 0.0 | — |
| Financing Activities | 53,807,000.0 | 133,522,000.0 | 33,017,000.0 | 0.0 | — |